Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025

New additions streamline data transfer with lesion details, helping make information more accessible for care teams

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 - December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added lesion-level reporting, discuss new clinical research findings, and provide guidance on the plaque analysis Category I CPT code effective January 1, 2026.

The PowerScribe integration will help simplify clinic workflows by mapping and transferring information from Coronary Computed Tomography Angiography (CCTA) reports to PowerScribe templates. This helps reduce manual data entry requirements and transcription errors, enabling efficient report generation and clinical documentation.

The updated lesion-specific details in the provider report provide clinical information about each identified lesion, giving providers comprehensive data with visual references to aid treatment planning. This anatomical detail can enable precise clinical decision-making based on morphological and compositional plaque characteristics at their fingertips.

Cleerly will also present new research at RSNA titled "Prognostic Utility of Coronary Calcification in the Consideration of Underlying Non-calcified Plaque Burden." Presented by Dr. Parth Patel, the abstract offers new data comparing risk prediction of coronary artery calcium scores with non-calcified plaque volume using AI quantitative computed tomography (AI-QCT).

Cleerly representatives at RSNA will also be available to discuss the recently announced Final Rule for the Category I CPT code for plaque analysis (75577), which goes into effect January 1, 2026. The CY 2026 Physician Fee Schedule (PFS) Final Rule sets the global reimbursement rate at $1,026 for plaque analysis. Cleerly initiated this advancement by submitting an application to the American Medical Association's CPT Editorial Panel in June 2024, and the Panel voted to accept the new code, elevating the technology from Category III to Category I status.

Visit Cleerly at Booth #8039 during RSNA 2025 to experience these new product updates firsthand and learn more about the upcoming reimbursement changes. For more information, visit www.cleerlyhealth.com.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.